CMS Moves Forward with 3rd Round of Medicare Drug Negotiations

Why It Matters

The negotiations could substantially lower Medicare’s drug spend, setting a precedent for federal price controls on specialty medicines and reshaping pharma pricing strategies.

Key Takeaways

• All 15 selected drugs have manufacturer participation
• Negotiations target high-cost, single-source drugs without competition
• Final agreements due Nov 1 2026; prices effective 2028
• CMS expands orphan drug exclusions and uses MA data
• Prior rounds projected $6 billion Medicare savings

Pulse Analysis

The Inflation Reduction Act gave CMS the authority to negotiate prices for the nation’s most expensive, single‑source drugs, a power that has quickly become a cornerstone of federal cost‑containment policy. By the third negotiation cycle, the program has matured to include a broader set of therapeutics, ranging from immunology agents like Cosentyx to oncology staples such as Lenvima. The inclusion of a renegotiation for Xolair reflects CMS’s willingness to revisit prior agreements, while the expanded orphan‑drug exclusions aim to balance innovation incentives with fiscal responsibility.

In this round, all fifteen selected manufacturers have agreed to engage, signaling industry acceptance of the negotiation framework despite concerns about profit margins. The list features a mix of biologics, small‑molecule therapies, and specialty injectables, each representing significant Medicare Part B or D spend. CMS’s updated guidance, released September 30, 2025, incorporates Medicare Advantage encounter data, providing a more accurate picture of real‑world utilization. The timeline—initial offers by June 1, 2026, and final contracts by Nov 1, 2026—compresses the negotiation window, pushing price implementation to 2028 and giving beneficiaries a clearer horizon for cost expectations.

If the third‑cycle agreements mirror the projected savings of earlier rounds, Medicare could see another multi‑billion‑dollar reduction in drug expenditures, easing pressure on the federal budget and potentially lowering out‑of‑pocket costs for seniors. For pharmaceutical companies, the program introduces a new pricing benchmark that may influence launch strategies, especially for drugs lacking generic competition. The broader market may respond with accelerated biosimilar development or strategic pricing adjustments, while patients and clinicians will closely monitor how negotiated prices affect drug accessibility and therapeutic choices. The evolving negotiation landscape thus represents a pivotal shift toward more transparent, value‑based drug pricing in the United States.